

# A Method for the Identification of Variants in Alzheimer's Disease Candidate Genes and Transcripts Using Hybridization Capture Combined with Long-Read Sequencing

Steve Kujawa<sup>1</sup>, Jenny Ekholm<sup>1</sup>, Kevin Eng<sup>1</sup>, Ting Hon<sup>1</sup>, Elizabeth Tseng<sup>1</sup>, Aaron Wenger<sup>1</sup>, Kristina Giorda<sup>2</sup>, Jiashi Wang<sup>2</sup> & Mirna Jarosz<sup>2</sup>  
<sup>1</sup>PacBio, 1380 Willow Road, Menlo Park, CA 94025  
<sup>2</sup>Integrated DNA Technologies, 1710 Commercial Park, Coralville, IA, 52241



## Introduction

Alzheimer's disease (AD) is a devastating neurodegenerative disease that is genetically complex. Although great progress has been made in identifying fully penetrant mutations in genes that cause early-onset AD, these still represent a very small percentage of AD cases. Large-scale, genome-wide association studies (GWAS) have identified at least 20 additional genetic risk loci for the more common form of late-onset AD. However, the identified SNPs are typically not the actual risk variants, but are in linkage disequilibrium with the presumed causative variants<sup>1</sup>.

Long-read sequencing together with hybrid-capture targeting technologies provides a powerful combination to target candidate genes/transcripts of interest. Here we present a method for capturing genomic DNA (gDNA) and cDNA from two AD subjects using a panel of probes targeting 35 AD candidate genes. By combining xGen® Lockdown® probes with SMRT Sequencing, we provide completely sequenced candidate genes as well as their corresponding full-length transcripts. Furthermore, we are able to take advantage of heterozygous variants to phase the genes and their corresponding transcript isoforms into their respective haplotypes.

## Materials & Methods

A custom panel of 35 AD genes (Table 1) was designed using IDT xGen Lockdown probes. Probes were placed approximately every 1 kb (Figure 1) and designed to cover the entire gene (exons, introns and regulatory regions).

### Genes Included in the Panel

ABCA7	APH1	APOE	APP	BACE1
BIN1	CASS4	BSG	CD2AP	CD33
CELF1	CLU	CR1	EPHA1	FERMT2
GRN	HLA-DRB1	HLA-DRB5	INPP5D	MAPT
MEF2C-AS1	MS4A6A	NCSTN	NME8	PICALM
PSEN1	PSEN2	PTK2B	RIN3	SLC24A4
SNCA	SORL1	TOMM40	TREM2	ZCWPW1

Table 1. The custom AD panel includes 35 genes.




Figure 1. Probe design for *PSEN1*. 77 probes were evenly spaced across the ~90 kb gene.

Two subjects were sequenced during this experiment (Table 2). For each subject, gDNA was captured with the custom AD panel according to the published protocol<sup>2</sup> and sequenced on eight PacBio RS II SMRT Cells. Separately, for each subject, RNA was converted to cDNA, captured with the custom AD panel according to the published protocol<sup>3</sup> and sequenced on four PacBio RS II SMRT Cells.

Subject	Source of Genomic DNA	Source of Total RNA
#1 87 year-old male	Brain, Frontal Lobe	Brain, Temporal Lobe
#2 93 year-old female	Skeletal Muscle	Brain, Temporal Lobe

Table 2. gDNA and total RNA from two AD subjects were purchased from BioChain Institute, Inc.

## Results - Genes

Reads from the gDNA from Subjects 1 and 2 were mapped to the hg38 reference genome using NGM-LR. Structural variants >50bp were called using PBHoney Spots (Table 3). Only variants in the target regions were considered.

	# Events	# Unique Genes
Deletions >50 bp	15	10
Insertions >50 bp	16	8

Table 3. SVs >50 bp Observed in the 35 AD Genes from Subjects 1 & 2. 31 unique SVs were observed, ranging in size from 65 bp to multiple kilobases.




Figure 2. gDNA of *PSEN1* from Subject 1. Nearly complete coverage across the entire ~90 kb gene. SNPs and structural variants, including a 900 bp homozygous deletion in the first intron (red arrow), are observed.

## Results - Transcripts

The captured cDNA from Subjects 1 and 2 were run through the Iso-Seq (ToFU) bioinformatics pipeline to obtain Quiver-polished, full-length, high-quality transcript sequences. Sequences were then mapped to the hg38 genome and filtered with criteria: (1) alignment coverage  $\geq 99\%$ ; (2) alignment identity  $\geq 95\%$ ; (3) at least 5 FL read support; (4) is not a 5' degraded product; and (5) overlaps the probe target region. This resulted in a total of 515 isoforms from Subject 1 and 507 isoforms from Subject 2. To compare with existing annotation, we selected all Gencode v25 transcripts from the target genes with an annotated transcript support level of 1 (most reliable annotation, all junctions supported by at least one mRNA evidence), resulting in 111 isoforms. We compared the isoforms among the three samples and show the # of shared isoforms (which must agree in both the number of exons and the junction sites) between them (Figure 3).




Figure 3. Comparison of isoforms observed in Subjects 1 & 2 with Level 1 isoforms in Gencode v25.



Figure 4. Haplotype 1 (5 isoforms) and Haplotype 2 (21 isoforms) for *MAPT* transcripts from Subject 1. Heterozygous SNPs can be used to haplotype the transcripts. A novel exon (red arrows) was observed in three of the five isoforms in Haplotype 1 and not observed in any of the 21 isoforms in Haplotype 2.

## Results – Haplotype Variants

After alignment to the hg38 genome, heterozygous variants can be used to further assign the gDNA and transcripts to their appropriate haplotype. As the average fragment size of the captured gDNA is ~6kb, it is possible to phase regions that are multiple, tens of kilobases in length. Full-length transcripts are easily phased if a heterozygous SNP is captured in an exon or retained intron.




Figure 5. *MAPT* Genes & Transcripts from Haplotype 1 of Subject 1. Heterozygous SNPs can be used to phase the genomic DNA and transcripts to their appropriate haplotype. Five unique isoforms were observed from haplotype 1. Three of these isoforms contained a unique exon (red arrow) that was only present in haplotype 1. These exons were flanked by the canonical "AG" and "GT" splice sites in the gDNA.




Figure 6. *MAPT* Genes & Transcripts from Haplotype 2 of Subject 1. Heterozygous SNPs can be used to phase the genomic DNA and transcripts to their appropriate haplotype. Once phased, variants such as this 100 bp homozygous deletion (red arrow) can be studied to better understand their potential impact on transcript isoform production.

## Conclusion

Combining xGen Lockdown probes with SMRT Sequencing provides a method for completely sequenced candidate genes and their corresponding full-length transcripts

This method enables:

- Detection of a broad range of genomic variants, from SNPs to multi-kilobase insertions and deletions
- Detection of novel transcript isoforms, including novel exons
- Assignment of variants and transcripts isoforms to their specific haplotypes

## References

1. Van Cauwenberghe C, et al. (2015). The genetic landscape of Alzheimer disease: clinical implications and perspectives. *Genet Med*, (18), 421-430
2. <http://tinyurl.com/zw8vza6>
3. <http://tinyurl.com/zy9y4py>

## Acknowledgements

The authors would like to thank everyone who helped generate data for the poster.